|Trade names||Aralen, other|
|Other names||Chloroquine phosphate|
|Defined daily dose||500 mg (by mouth) or|
500 mg (parenteral)
|Elimination half-life||1-2 months|
|Chemical and physical data|
|Molar mass||319.872 g·mol−1|
|3D model (JSmol)|
Chloroquine is a medication primarily used to prevent and treat malaria in areas where malaria remains sensitive to its effects. Certain types of malaria, resistant strains, and complicated cases typically require different or additional medication. Chloroquine is also occasionally used for amebiasis that is occurring outside the intestines, rheumatoid arthritis, and lupus erythematosus. While it has not been formally studied in pregnancy, it appears safe. It is also being studied to treat COVID-19 as of 2020. It is taken by mouth.
Common side effects include muscle problems, loss of appetite, diarrhea, and skin rash. Serious side effects include problems with vision, muscle damage, seizures, and low blood cell levels. Chloroquine is a member of the drug class 4-aminoquinoline. As an antimalarial, it works against the asexual form of the malaria parasite in the stage of its life cycle within the red blood cell. How it works in rheumatoid arthritis and lupus erythematosus is unclear.
Chloroquine was discovered in 1934 by Hans Andersag. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. The wholesale cost in the developing world is about US$0.04. In the United States, it costs about US$5.30 per dose.
Chloroquine has been used in the treatment and prevention of malaria from Plasmodium vivax, P. ovale, and P. malariae. It is generally not used for Plasmodium falciparum as there is widespread resistance to it.
Chloroquine has been extensively used in mass drug administrations, which may have contributed to the emergence and spread of resistance. It is recommended to check if chloroquine is still effective in the region prior to using it. In areas where resistance is present, other antimalarials, such as mefloquine or atovaquone, may be used instead. The Centers for Disease Control and Prevention recommend against treatment of malaria with chloroquine alone due to more effective combinations.
In treatment of amoebic liver abscess, chloroquine may be used instead of or in addition to other medications in the event of failure of improvement with metronidazole or another nitroimidazole within 5 days or intolerance to metronidazole or a nitroimidazole.
The conversion is 155 mg of the base equals 200 mg of the sulfate or 250 mg of the phophate or diphosphate form.
Side effects include blurred vision, nausea, vomiting, abdominal cramps, headache, diarrhea, swelling legs/ankles, shortness of breath, pale lips/nails/skin, muscle weakness, easy bruising/bleeding, hearing and mental problems.
- Unwanted/uncontrolled movements (including tongue and face twitching) 
- Deafness or tinnitus.
- Nausea, vomiting, diarrhea, abdominal cramps
- Mental/mood changes (such as confusion, personality changes, unusual thoughts/behavior, depression, feeling being watched, hallucinating)
- Signs of serious infection (such as high fever, severe chills, persistent sore throat)
- Skin itchiness, skin color changes, hair loss, and skin rashes.
- Chloroquine-induced itching is very common among black Africans (70%), but much less common in other races. It increases with age, and is so severe as to stop compliance with drug therapy. It is increased during malaria fever; its severity is correlated to the malaria parasite load in blood. Some evidence indicates it has a genetic basis and is related to chloroquine action with opiate receptors centrally or peripherally.
- Unpleasant metallic taste
- This could be avoided by "taste-masked and controlled release" formulations such as multiple emulsions.
- Chloroquine retinopathy
- Electrocardiographic changes
- This manifests itself as either conduction disturbances (bundle-branch block, atrioventricular block) or Cardiomyopathy – often with hypertrophy, restrictive physiology, and congestive heart failure. The changes may be irreversible. Only two cases have been reported requiring heart transplantation, suggesting this particular risk is very low. Electron microscopy of cardiac biopsies show pathognomonic cytoplasmic inclusion bodies.
- Pancytopenia, aplastic anemia, reversible agranulocytosis, low blood platelets, neutropenia.
Chloroquine has not been shown to have any harmful effects on the fetus when used in the recommended doses for malarial prophylaxis. Small amounts of chloroquine are excreted in the breast milk of lactating women. However, this drug can be safely prescribed to infants, the effects are not harmful. Studies with mice show that radioactively tagged chloroquine passed through the placenta rapidly and accumulated in the fetal eyes which remained present five months after the drug was cleared from the rest of the body. Women who are pregnant or planning on getting pregnant are still advised against traveling to malaria-risk regions.
There is not enough evidence to determine whether chloroquine is safe to be given to people aged 65 and older. Since it is cleared by the kidneys, toxicity should be monitored carefully in people with poor kidney functions.
- Ampicillin- levels may be reduced by chloroquine;
- Antacids- may reduce absorption of chloroquine;
- Cimetidine- may inhibit metabolism of chloroquine; increasing levels of chloroquine in the body;
- Cyclosporine- levels may be increased by chloroquine; and
- Mefloquine- may increase risk of convulsions.
Chloroquine, in overdose, has a risk of death of about 20%. It is rapidly absorbed from the gut with an onset of symptoms generally within an hour. Symptoms of overdose may include sleepiness, vision changes, seizures, stopping of breathing, and heart problems such as ventricular fibrillation and low blood pressure. Low blood potassium may also occur.
While the usual dose of chloroquine used in treatment is 10 mg/kg, toxicity begins to occur at 20 mg/kg, and death may occur at 30 mg/kg. In children as little as a single tablet can cause problems.
Treatment recommendations include early mechanical ventilation, cardiac monitoring, and activated charcoal. Intravenous fluids and vasopressors may be required with epinephrine being the vasopressor of choice. Seizures may be treated with benzodiazepines. Intravenous potassium chloride may be required, however this may result in high blood potassium later in the course of the disease. Dialysis has not been found to be useful.
Absorption of chloroquine is rapid and primarily happens in the gastrointestinal tract. It is widely distributed in body tissues. Protein binding in plasma ranges from 46% to 79%. Its metabolism is partially hepatic, giving rise to its main metabolite, desethylchloroquine. Its excretion is ≥50% as unchanged drug in urine, where acidification of urine increases its elimination. It has a very high volume of distribution, as it diffuses into the body's adipose tissue.
Accumulation of the drug may result in deposits that can lead to blurred vision and blindness. It and related quinines have been associated with cases of retinal toxicity, particularly when provided at higher doses for longer times. With long-term doses, routine visits to an ophthalmologist are recommended.
Chloroquine is also a lysosomotropic agent, meaning it accumulates preferentially in the lysosomes of cells in the body. The pKa for the quinoline nitrogen of chloroquine is 8.5, meaning it is about 10% deprotonated at physiological pH (per the Henderson-Hasselbalch equation).[original research?] This decreases to about 0.2% at a lysosomal pH of 4.6.[original research?] Because the deprotonated form is more membrane-permeable than the protonated form, a quantitative "trapping" of the compound in lysosomes results.
Mechanism of action
The lysosomotropic character of chloroquine is believed to account for much of its antimalarial activity; the drug concentrates in the acidic food vacuole of the parasite and interferes with essential processes. Its lysosomotropic properties further allow for its use for in vitro experiments pertaining to intracellular lipid related diseases, autophagy, and apoptosis.
Inside red blood cells, the malarial parasite, which is then in its asexual lifecycle stage, must degrade hemoglobin to acquire essential amino acids, which the parasite requires to construct its own protein and for energy metabolism. Digestion is carried out in a vacuole of the parasitic cell.
Hemoglobin is composed of a protein unit (digested by the parasite) and a heme unit (not used by the parasite). During this process, the parasite releases the toxic and soluble molecule heme. The heme moiety consists of a porphyrin ring called Fe(II)-protoporphyrin IX (FP). To avoid destruction by this molecule, the parasite biocrystallizes heme to form hemozoin, a nontoxic molecule. Hemozoin collects in the digestive vacuole as insoluble crystals.
Chloroquine enters the red blood cell by simple diffusion, inhibiting the parasite cell and digestive vacuole. Chloroquine then becomes protonated (to CQ2+), as the digestive vacuole is known to be acidic (pH 4.7); chloroquine then cannot leave by diffusion. Chloroquine caps hemozoin molecules to prevent further biocrystallization of heme, thus leading to heme buildup. Chloroquine binds to heme (or FP) to form the FP-chloroquine complex; this complex is highly toxic to the cell and disrupts membrane function. Action of the toxic FP-chloroquine and FP results in cell lysis and ultimately parasite cell autodigestion. Parasites that do not form hemozoin are therefore resistant to chloroquine.
Resistance in malaria
Since the first documentation of P. falciparum chloroquine resistance in the 1950s, resistant strains have appeared throughout East and West Africa, Southeast Asia, and South America. The effectiveness of chloroquine against P. falciparum has declined as resistant strains of the parasite evolved. They effectively neutralize the drug via a mechanism that drains chloroquine away from the digestive vacuole. Chloroquine-resistant cells efflux chloroquine at 40 times the rate of chloroquine-sensitive cells; the related mutations trace back to transmembrane proteins of the digestive vacuole, including sets of critical mutations in the P. falciparum chloroquine resistance transporter (PfCRT) gene. The mutated protein, but not the wild-type transporter, transports chloroquine when expressed in Xenopus oocytes (frog's eggs) and is thought to mediate chloroquine leak from its site of action in the digestive vacuole. Resistant parasites also frequently have mutated products of the ABC transporter P. falciparum multidrug resistance (PfMDR1) gene, although these mutations are thought to be of secondary importance compared to Pfcrt. Verapamil, a Ca2+ channel blocker, has been found to restore both the chloroquine concentration ability and sensitivity to this drug. Recently, an altered chloroquine-transporter protein CG2 of the parasite has been related to chloroquine resistance, but other mechanisms of resistance also appear to be involved. Research on the mechanism of chloroquine and how the parasite has acquired chloroquine resistance is still ongoing, as other mechanisms of resistance are likely.
Chloroquine has antiviral effects against some viruses. It increases late endosomal and lysosomal pH, resulting in impaired release of the virus from the endosome or lysosome – release of the virus requires a low pH. The virus is therefore unable to release its genetic material into the cell and replicate.
Against rheumatoid arthritis, it operates by inhibiting lymphocyte proliferation, phospholipase A2, antigen presentation in dendritic cells, release of enzymes from lysosomes, release of reactive oxygen species from macrophages, and production of IL-1.
In Peru, the indigenous people extracted the bark of the Cinchona tree (Cinchona officinalis) and used the extract to fight chills and fever in the seventeenth century. In 1633 this herbal medicine was introduced in Europe, where it was given the same use and also began to be used against malaria. The quinoline antimalarial drug quinine was isolated from the extract in 1820, and chloroquine is an analogue of this.
Chloroquine was discovered in 1934, by Hans Andersag and coworkers at the Bayer laboratories, who named it Resochin. It was ignored for a decade, because it was considered too toxic for human use. Instead, the DAK used the chloroquine analogue 3-methyl-chloroquine, known as Sontochin. After Allied forces arrived in Tunis, Sontochin fell into the hands of Americans, who sent the material back to the United States for analysis, leading to renewed interest in chloroquine. United States government-sponsored clinical trials for antimalarial drug development showed unequivocally that chloroquine has a significant therapeutic value as an antimalarial drug. It was introduced into clinical practice in 1947 for the prophylactic treatment of malaria.
Society and culture
Chloroquine comes in tablet form as the phosphate, sulfate, and hydrochloride salts. Chloroquine is usually dispensed as the phosphate.
Brand names include Chloroquine FNA, Resochin, Dawaquin, and Lariago.
Chloroquine, in various chemical forms, is used to treat and control surface growth of anemones and algae, and many protozoan infections in aquariums, e.g. the fish parasite Amyloodinium ocellatum.
There is limited evidence on the use of chloroquine in people with COVID-19. Chloroquine has been approved by Chinese, South Korean and Italian health authorities for the experimental treatment of COVID-19. These agencies noted contraindications for people with heart disease or diabetes. However, use of chloroquine is only recommended in the setting of an approved trial or under the details outlined by Monitored Emergency Use of Unregistered Interventions. On 1 April 2020, the European Medicines Agency (EMA) issued guidance that chloroquine and hydroxychloroquine are only to be used in clinical trials or emergency use programs. On 29 May 2020, the EMA stated that patients already taking chloroquine for unrelated conditions, should continue to do so, always under the supervision of their doctor.
Health experts warned against the misuse of the non-pharmaceutical versions of chloroquine phosphate after a husband and wife consumed a fish tank antiparasitic containing chloroquine phosphate on 24 March, with the intention of it being prophylaxis against COVID-19. One of them died and the other was hospitalized. Chloroquine has a relatively narrow therapeutic index and it can be toxic at levels not much higher than those used for treatment—which raises the risk of inadvertent overdose. On 27 March 2020, the US Food and Drug Administration (FDA) issued guidance, "do not use chloroquine phosphate intended for fish as treatment for COVID-19 in humans".
The FDA has cautioned against using the drug outside a hospital setting or clinical trial after reviewing adverse events including ventricular tachycardia, ventricular fibrillation, and deaths. On 28 March 2020 the FDA authorized the use of hydroxychloroquine and chloroquine under an emergency use authorization (EUA). The treatment has not been approved by the FDA. The experimental treatment is authorized only for emergency use for people who are hospitalized but not able to receive treatment in a clinical trial. In anticipation of product shortages, the FDA issued product-specific guidance for chloroquine phosphate and for hydroxychloroquine sulfate for generic drug manufacturers. On 15 June 2020, the FDA revoked the emergency use authorization for chloroquine and hydroxychloroquine.
A study of chloroquine in 81 people hospitalized before confirmation of COVID-19, compared high dose chloroquine to low-dose chloroquine. People were also treated with ceftriaxone and azithromycin. By the sixth day of treatment, seven people in the high-dose group and four people in the low-dose group had died, leading to an immediate end to the trial.
On 29 May 2020, the EMA issued a public health statement reminding healthcare professionals to closely monitor people with COVID-19 who are receiving chloroquine. It also published a list of references of observational studies of chloroquine and hydroxychloroquine in people with COVID-19.
On 4 June 2020, there was a retraction of a major multinational analysis that clearly stated having found no clinical benefit while administrating chloroquine, hydroxychloroquine, alone or accompanied by a macrolide and in contrast did raise the percentages of high risk side effects, most prominently cardiac dysrrythmias.
On 15 June 2020, the FDA updated the fact sheets for the emergency use authorization of remdesivir to warn that using chloroquine or hydroxychloroquine with remdesivir may reduce the antiviral activity of remdesivir.
Chloroquine has been under investigation for its purposed role of a potential COVID-19 therapeutic regimen. One of the trials currently going on is the Solidarity Trial, organised and performed by WHO. On 23 May 2020, the Trial's directors decided to temporarily pause hydroxychloroquine administration, due to safety concerns.
Chloroquine had been also proposed as a treatment for SARS, with in vitro tests inhibiting the SARS-CoV virus. In October 2004, a group of researchers at the Rega Institute for Medical Research published a report on chloroquine, stating that chloroquine acts as an effective inhibitor of the replication of the severe acute respiratory syndrome coronavirus (SARS-CoV) in vitro.
The radiosensitizing and chemosensitizing properties of chloroquine are beginning to be exploited in anticancer strategies in humans. In biomedicinal science, chloroquine is used for in vitro experiments to inhibit lysosomal degradation of protein products.
- "CHLOROQUINE sulfate or phosphate oral - Essential drugs". medicalguidelines.msf.org. Retrieved 30 August 2020.
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 22 September 2020.
- "Aralen Phosphate". The American Society of Health-System Pharmacists. Archived from the original on 8 December 2015. Retrieved 2 December 2015.
- "Chloroquine Use During Pregnancy". Drugs.com. Archived from the original on 16 April 2019. Retrieved 16 April 2019.
There are no controlled data in human pregnancies.
- Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S (March 2020). "A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19". Journal of Critical Care. 57: 279–283. doi:10.1016/j.jcrc.2020.03.005. PMID 32173110.
- Mittra RA, Mieler WF (2013). "Chapter 89 – Drug Toxicity of the Posterior Segment". Retina (Fifth ed.). W.B. Saunders. pp. 1532–1554. doi:10.1016/B978-1-4557-0737-9.00089-8. ISBN 978-1-4557-0737-9. Retrieved 25 March 2020.
- Manson P, Cooke G, Zumla A, eds. (2009). Manson's tropical diseases (22nd ed.). [Edinburgh]: Saunders. p. 1240. ISBN 978-1-4160-4470-3. Archived from the original on 2 November 2018. Retrieved 9 September 2017.
- Bhattacharjee M (2016). Chemistry of Antibiotics and Related Drugs. Springer. p. 184. ISBN 978-3-319-40746-3. Archived from the original on 1 November 2018. Retrieved 9 September 2017.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06.
- "Chloroquine (Base)". International Drug Price Indicator Guide. Archived from the original on 27 August 2018. Retrieved 4 December 2015.
- "Frequently Asked Questions (FAQs): If I get malaria, will I have it for the rest of my life?". US Centers for Disease Control and Prevention. 8 February 2010. Archived from the original on 13 May 2012. Retrieved 14 May 2012.
- Plowe CV (2005). "Antimalarial drug resistance in Africa: strategies for monitoring and deterrence". Malaria: Drugs, Disease and Post-genomic Biology. Current Topics in Microbiology and Immunology. 295. pp. 55–79. doi:10.1007/3-540-29088-5_3. ISBN 3-540-25363-7. PMID 16265887.
- Uhlemann AC, Krishna S (2005). "Antimalarial multi-drug resistance in Asia: mechanisms and assessment". Malaria: Drugs, Disease and Post-genomic Biology. Current Topics in Microbiology and Immunology. 295. pp. 39–53. doi:10.1007/3-540-29088-5_2. ISBN 3-540-25363-7. PMID 16265886.
- "Chloroquine phosphate tablet – chloroquine phosphate tablet, coated". dailymed.nlm.nih.gov. Archived from the original on 8 December 2015. Retrieved 4 November 2015.
- CDC. Health information for international travel 2001–2002. Atlanta, Georgia: U.S. Department of Health and Human Services, Public Health Service, 2001.
- Amebic Hepatic Abscesses~treatment at eMedicine
- "Drugs & Medications". www.webmd.com. Retrieved 22 March 2020.
- "Chloroquine Side Effects: Common, Severe, Long Term". Drugs.com. Retrieved 22 March 2020.
- "Chloroquine: MedlinePlus Drug Information". medlineplus.gov. Retrieved 22 March 2020.
- Ajayi AA (September 2000). "Mechanisms of chloroquine-induced pruritus". Clinical Pharmacology and Therapeutics. 68 (3): 336. PMID 11014416.
- Vaziri A, Warburton B (1994). "Slow release of chloroquine phosphate from multiple taste-masked W/O/W multiple emulsions". Journal of Microencapsulation. 11 (6): 641–8. doi:10.3109/02652049409051114. PMID 7884629.
- Tönnesmann E, Kandolf R, Lewalter T (June 2013). "Chloroquine cardiomyopathy – a review of the literature". Immunopharmacology and Immunotoxicology. 35 (3): 434–42. doi:10.3109/08923973.2013.780078. PMID 23635029.
- "Chloroquine phosphate tablet". DailyMed. 8 October 2018. Retrieved 7 April 2020.
- "Malaria – Chapter 3 – 2016 Yellow Book". wwwnc.cdc.gov. Archived from the original on 14 January 2016. Retrieved 11 November 2015.
- Ullberg S, Lindquist NG, Sjòstrand SE (September 1970). "Accumulation of chorio-retinotoxic drugs in the foetal eye". Nature. 227 (5264): 1257–8. Bibcode:1970Natur.227.1257U. doi:10.1038/2271257a0. PMID 5452818.
- Ling Ngan Wong, A; Tsz Fung Cheung, I; Graham, CA (February 2008). "Hydroxychloroquine overdose: case report and recommendations for management". European Journal of Emergency Medicine. 15 (1): 16–8. doi:10.1097/MEJ.0b013e3280adcb56. PMID 18180661.
- Smith, ER; Klein-Schwartz, W (May 2005). "Are 1-2 dangerous? Chloroquine and hydroxychloroquine exposure in toddlers". The Journal of Emergency Medicine. 28 (4): 437–43. doi:10.1016/j.jemermed.2004.12.011. PMID 15837026.
- "Chloroquine". §6.1 Absorption by route of exposure. Retrieved 24 April 2020.
- S.A., Adelusi; L.A., Salako (22 February 1982). "Tissue and blood concentrations of chloroquine following chronic administration in the rat". Journal of Pharmacy and Pharmacology. 34 (11): 733–5. doi:10.1111/j.2042-7158.1982.tb06211.x. PMID 6129306.
- Walker, O.; Birkett, D.J.; Alvan, G.; Gustafsson, L.L.; Sjoqvist, F. (1983). "Characterization of chloroquine plasma protein binding in man". British Journal of Clinical Pharmacology. 15 (3): 375–7. doi:10.1111/j.1365-2125.1983.tb01513.x. PMC 1427768. PMID 6849768.
- Denis, Projean; Bruno, Baune; Robert, Farinotti; Jean-Pierre, Flinois; Philippe, Beaune; Anne-Marie, Taburet; Julie, Ducharme (June 2003). "In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation". Drug Metabolism and Disposition. 31 (6): 748–54. doi:10.1124/dmd.31.6.748. PMID 12756207.
- Chen PM, Gombart ZJ, Chen JW (March 2011). "Chloroquine treatment of ARPE-19 cells leads to lysosome dilation and intracellular lipid accumulation: possible implications of lysosomal dysfunction in macular degeneration". Cell & Bioscience. 1 (1): 10. doi:10.1186/2045-3701-1-10. PMC 3125200. PMID 21711726.
- Kurup P, Zhang Y, Xu J, Venkitaramani DV, Haroutunian V, Greengard P, et al. (April 2010). "Aβ-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61". The Journal of Neuroscience. 30 (17): 5948–57. doi:10.1523/JNEUROSCI.0157-10.2010. PMC 2868326. PMID 20427654.
- Kim EL, Wüstenberg R, Rübsam A, Schmitz-Salue C, Warnecke G, Bücker EM, et al. (April 2010). "Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells". Neuro-Oncology. 12 (4): 389–400. doi:10.1093/neuonc/nop046. PMC 2940600. PMID 20308316.
- Hempelmann E (March 2007). "Hemozoin biocrystallization in Plasmodium falciparum and the antimalarial activity of crystallization inhibitors". Parasitology Research. 100 (4): 671–6. doi:10.1007/s00436-006-0313-x. PMID 17111179.
- Lin JW, Spaccapelo R, Schwarzer E, Sajid M, Annoura T, Deroost K, et al. (June 2015). "Replication of Plasmodium in reticulocytes can occur without hemozoin formation, resulting in chloroquine resistance" (PDF). The Journal of Experimental Medicine. 212 (6): 893–903. doi:10.1084/jem.20141731. PMC 4451122. PMID 25941254. Archived (PDF) from the original on 22 September 2017. Retrieved 4 November 2018.
- Martin RE, Marchetti RV, Cowan AI, Howitt SM, Bröer S, Kirk K (September 2009). "Chloroquine transport via the malaria parasite's chloroquine resistance transporter". Science. 325 (5948): 1680–2. Bibcode:2009Sci...325.1680M. doi:10.1126/science.1175667. PMID 19779197.
- Tripathi KD (2003). Essentials of Medical Pharmacology (fifth ed.). Jaypee Brothers Medical Publisher Ltd. pp. 739–740.
- Alcantara LM, Kim J, Moraes CB, Franco CH, Franzoi KD, Lee S, et al. (June 2013). "Chemosensitization potential of P-glycoprotein inhibitors in malaria parasites". Experimental Parasitology. 134 (2): 235–43. doi:10.1016/j.exppara.2013.03.022. PMID 23541983.
- Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R (November 2003). "Effects of chloroquine on viral infections: an old drug against today's diseases?". The Lancet. Infectious Diseases. 3 (11): 722–7. doi:10.1016/s1473-3099(03)00806-5. PMC 7128816. PMID 14592603.
- Al-Bari MA (February 2017). "Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases". Pharmacology Research & Perspectives. 5 (1): e00293. doi:10.1002/prp2.293. PMC 5461643. PMID 28596841.
- Fredericksen BL, Wei BL, Yao J, Luo T, Garcia JV (November 2002). "Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus". Journal of Virology. 76 (22): 11440–6. doi:10.1128/JVI.76.22.11440-11446.2002. PMC 136743. PMID 12388705.
- Xue J, Moyer A, Peng B, Wu J, Hannafon BN, Ding WQ (1 October 2014). "Chloroquine is a zinc ionophore". PLOS ONE. 9 (10): e109180. Bibcode:2014PLoSO...9j9180X. doi:10.1371/journal.pone.0109180. PMC 4182877. PMID 25271834.
- te Velthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ (November 2010). "Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture". PLOS Pathogens. 6 (11): e1001176. doi:10.1371/journal.ppat.1001176. PMC 2973827. PMID 21079686.
- Huang Z, Srinivasan S, Zhang J, Chen K, Li Y, Li W, et al. (2012). "Discovering thiamine transporters as targets of chloroquine using a novel functional genomics strategy". PLOS Genetics. 8 (11): e1003083. doi:10.1371/journal.pgen.1003083. PMC 3510038. PMID 23209439.
- Fern K (2010–2020). "Cinchona officinalis – L." Plans for a Future. Archived from the original on 25 August 2017. Retrieved 2 February 2020.CS1 maint: date format (link)
- Kouznetsov V (2008). "Antimalarials: construction of molecular hybrids based on chloroquine" (PDF). Universitas Scientiarum: 1. Archived (PDF) from the original on 22 February 2020. Retrieved 22 February 2020 – via scielo.
- Krafts K, Hempelmann E, Skórska-Stania A (July 2012). "From methylene blue to chloroquine: a brief review of the development of an antimalarial therapy". Parasitology Research. 111 (1): 1–6. doi:10.1007/s00436-012-2886-x. PMID 22411634.
- Sneader W (2005). Drug Discovery. A History. Wiley. ISBN 0-471-89980-1.
- Pou S, Winter RW, Nilsen A, Kelly JX, Li Y, Doggett JS, et al. (July 2012). "Sontochin as a guide to the development of drugs against chloroquine-resistant malaria". Antimicrobial Agents and Chemotherapy. 56 (7): 3475–80. doi:10.1128/AAC.00100-12. PMC 3393441. PMID 22508305.
- "The History of Malaria, an Ancient Disease". Centers for Disease Control. 29 July 2019. Archived from the original on 28 August 2010.
- "Chloroquine". nih.gov. National Institutes of Health. Retrieved 24 March 2020.
- "Ipca Laboratories: Formulations – Branded". Archived from the original on 6 April 2019. Retrieved 14 March 2020.
- Hemdal J. "Aquarium Fish: Chloroquine: A "New" Drug for Treating Fish Diseases". Advanced Aquarist. Archived from the original on 15 March 2013. Retrieved 26 March 2020.
- Francis-Floyd R, Floyd MR. "Amyloodinium ocellatum, an Important Parasite of Cultured Marine Fish" (PDF). agrilife.org. Archived from the original (PDF) on 1 June 2015. Retrieved 24 March 2020.
- "Assessment of Evidence for COVID-19-Related Treatments: Updated 4/3/2020". ASHP. Retrieved 7 April 2020.
- "Coronavirus COVID-19 (SARS-CoV-2)". Johns Hopkins ABX Guide. Retrieved 12 April 2020.
- "Physicians work out treatment guidelines for coronavirus". m.koreabiomed.com (in 한국어). 13 February 2020. Archived from the original on 17 March 2020. Retrieved 18 March 2020.
- "Azioni intraprese per favorire la ricerca e l'accesso ai nuovi farmaci per il trattamento del COVID-19". aifa.gov.it (in italiano). Retrieved 18 March 2020.
- "Plaquenil (hydroxychloroquine sulfate) dose, indications, adverse effects, interactions... from PDR.net". pdr.net. Archived from the original on 18 March 2020. Retrieved 19 March 2020.
- "COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes". European Medicines Agency (EMA). 1 April 2020. Retrieved 2 April 2020.
- FRANCISCO, Estela Miranda (29 May 2020). "COVID-19: reminder of the risks chloroquine and hydroxychloroquine". European Medicines Agency. Retrieved 10 June 2020.
- "A man died after ingesting a substance he thought would protect him from coronavirus". NBC News. Retrieved 25 March 2020.
- "Severe Illness Associated with Using Non-Pharmaceutical Chloroquine Phosphate to Prevent and Treat Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention. 28 March 2020. Retrieved 31 March 2020. This article incorporates text from this source, which is in the public domain.
- "Banner Health experts warn against self-medicating to prevent or treat COVID-19". Banner Health (Press release). 23 March 2020. Retrieved 25 March 2020.
- "FDA Letter to Stakeholders: Do Not Use Chloroquine Phosphate Intended for Fish as Treatment for COVID-19 in Humans". U.S. Food and Drug Administration (FDA). 27 March 2020. Retrieved 1 April 2020.
- Research, Center for Drug Evaluation and (24 April 2020). "FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems". FDA. Retrieved 26 April 2020.
- "Coronavirus (COVID-19) Update: Daily Roundup March 30, 2020". FDA. 30 March 2020.
- "Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention. 11 February 2020. Retrieved 9 April 2020.
- "Fact Sheet for Patients and Parent/Caregivers Emergency Use Authorization (EUA) of Chloroquine Phosphate for Treatment of COVID-19 in Certain Hospitalized Patients". FDA.
- "Product-Specific Guidances for Chloroquine Phosphate and Hydroxychloro". U.S. Food and Drug Administration. 13 April 2020. Retrieved 13 April 2020.
- "Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine". U.S. Food and Drug Administration (FDA) (Press release). 15 June 2020. Retrieved 15 June 2020.
- "EUA Archive". U.S. Food and Drug Administration (FDA). 15 June 2020. Retrieved 15 June 2020.
On June 15, 2020, based on FDA's continued review of the scientific evidence available for hydroxychloroquine sulfate (HCQ) and chloroquine phosphate (CQ) to treat COVID-19, FDA has determined that the statutory criteria for EUA as outlined in Section 564(c)(2) of the Food, Drug, and Cosmetic Act are no longer met. Specifically, FDA has determined that CQ and HCQ are unlikely to be effective in treating COVID-19 for the authorized uses in the EUA. Additionally, in light of ongoing serious cardiac adverse events and other serious side effects, the known and potential benefits of CQ and HCQ no longer outweigh the known and potential risks for the authorized use. This warrants revocation of the EUA for HCQ and CQ for the treatment of COVID-19.This article incorporates text from this source, which is in the public domain.
- "HCQ and CQ revocation letter" (PDF). U.S. Food and Drug Administration (FDA). 15 June 2020. Retrieved 15 June 2020.
- "Frequently Asked Questions on the Revocation of the Emergency Use Authorization for Hydroxychloroquine Sulfate and Chloroquine Phosphate" (PDF). U.S. Food and Drug Administration (FDA). 15 June 2020. Retrieved 15 June 2020.
- Thomas, Katie; Sheikh, Knvul (12 April 2020). "Small Chloroquine Study Halted Over Risk of Fatal Heart Complications". The New York Times.
- Sykes, Tom (13 April 2020). "Chloroquine Study Ended in Brazil After Patients Developed Irregular Heart Rates". The Daily Beast.
- "COVID-19: reminder of the risks chloroquine and hydroxychloroquine". European Medicines Agency (EMA). 29 May 2020. Retrieved 29 May 2020.
- "List of references of observational studies of chloroquine and hydroxychloroquine in COVID-19 patients" (PDF). European Medicines Agency (EMA). 29 May 2020. Retrieved 29 May 2020.
- Mehra MR, Ruschitzka F, Patel AN (June 2020). "Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis". Lancet. doi:10.1016/S0140-6736(20)31324-6. PMC 7274621. PMID 32511943.
- Mehra MR, Desai SS, Ruschitzka F, Patel AN (May 2020). "RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis". Lancet. doi:10.1016/S0140-6736(20)31180-6. PMC 7255293. PMID 32450107. Lay summary. (Retracted, see doi:10.1016/S0140-6736(20)31324-6, )
- "Coronavirus (COVID-19) Update: FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of a COVID-19 Treatment Authorized for Emergency Use". U.S. Food and Drug Administration (FDA) (Press release). 15 June 2020. Retrieved 15 June 2020. This article incorporates text from this source, which is in the public domain.
- ""Solidarity" clinical trial for COVID-19 treatments". www.who.int. Retrieved 10 June 2020.
- "Q&A : Hydroxychloroquine and COVID-19". www.who.int. Retrieved 10 June 2020.
- Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M (October 2004). "In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine". Biochemical and Biophysical Research Communications. 323 (1): 264–8. doi:10.1016/j.bbrc.2004.08.085. PMC 7092815. PMID 15351731.
- Devaux CA, Rolain JM, Colson P, Raoult D (March 2020). "New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?". International Journal of Antimicrobial Agents. 55 (5): 105938. doi:10.1016/j.ijantimicag.2020.105938. PMC 7118659. PMID 32171740.
- Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R (November 2003). "Effects of chloroquine on viral infections: an old drug against today's diseases?". The Lancet. Infectious Diseases. 3 (11): 722–7. doi:10.1016/S1473-3099(03)00806-5. PMC 7128816. PMID 14592603.
- Savarino A, Lucia MB, Giordano F, Cauda R (October 2006). "Risks and benefits of chloroquine use in anticancer strategies". The Lancet. Oncology. 7 (10): 792–3. doi:10.1016/S1470-2045(06)70875-0. PMID 17012039.
- Sotelo J, Briceño E, López-González MA (March 2006). "Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial". Annals of Internal Medicine. 144 (5): 337–43. doi:10.7326/0003-4819-144-5-200603070-00008. PMID 16520474.
"Adding chloroquine to conventional chemotherapy and radiotherapy for glioblastoma multiforme". Annals of Internal Medicine. 144 (5): I31. March 2006. doi:10.7326/0003-4819-144-5-200603070-00004. PMID 16520470.
|Wikimedia Commons has media related to [[commons:Lua error in Module:WikidataIB at line 497: attempt to index field 'wikibase' (a nil value).|Lua error in Module:WikidataIB at line 497: attempt to index field 'wikibase' (a nil value).]].|
- "Medicines for the Prevention of Malaria While Traveling – Chloroquine (Aralen)" (PDF) (Fact sheet). U.S. Centers for Disease Control and Prevention (CDC).
- The dictionary definition of chloroquine at Wiktionary